1. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency 
Chris G. McMahon, MBBS, FAChSHP, Neil Shusterman, MD, Brian Cohen, PhD 
The Journal of Sexual Medicine 
Volume 14, Issue 7, Pages (July 2017)
DOI: /j.jsxm
Copyright © 2017 The Authors Terms and Conditions

2. Figure 1
Panels A to D show concentration time curves for serum testosterone, free testosterone, DHT, and estradiol, respectively. Men deficient in androgens (serum testosterone concentration < 300 ng/dL) received implantation of 12 testosterone pellets (900 mg). Blood samples for pharmacokinetic evaluations were obtained before pellet implantation on day 1 and throughout the study at 8:00 am plus or minus 90 minutes. DHT = dihydrotestosterone.
The Journal of Sexual Medicine  , DOI: ( /j.jsxm )
Copyright © 2017 The Authors Terms and Conditions